[1] Chinese Expert Consensus Writing Group on Diagnosis and Treatment of Moyamoya Disease and Moyamoya Syndrome; Stroke Prevention and Treatment Expert Committee, National Health and Family Planning Commission. Chinese expert consensus on diagnosis and treatment of moyamoya disease and moyamoya syndrome (2017)[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2017, 33:541-547.[烟雾病和烟雾综合征诊断与治疗中国专家共识编写组, 国家卫生计生委脑卒中防治专家委员会缺血性卒中外科专业委员会. 烟雾病和烟雾综合征诊断与治疗中国专家共识(2017)[J]. 中华神经外科杂志, 2017, 33:541-547.] [2] Kuang W, Guo H. Research progress of cerebral hyperperfusion syndrome after direct cerebral vascular revascularization in moyamoya disease[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2020, 36:99-102.[匡伟, 郭华. 烟雾病直接脑血管重建术后脑高灌注综合征的研究进展[J]. 中华神经外科杂志, 2020, 36:99-102.] [3] Xu B, Song DL, Mao Y, Xu H, Liao YJ, Zhou LF. A new cerebral revascularization in treating moyamoya disease:superficial temporal artery-middle cerebral artery anastomosis combining with encephaloduromyosynangiosis[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2009, 25:102-105.[徐斌, 宋冬雷, 毛颖, 徐宏, 廖煜君, 周良辅. 颅内外血管吻合结合间接血管重建治疗烟雾病[J]. 中华神经外科杂志, 2009, 25:102-105.] [4] Farooq MU, Goshgarian C, Min J, Gorelick PB. Pathophysiology and management of reperfusion injury and hyperperfusion syndrome after carotid endarterectomy and carotid artery stenting[J]. Exp Transl Stroke Med, 2016, 8:7. [5] van Mook WN, Rennenberg RJ, Schurink GW, van Oostenbrugge RJ, Mess WH, Hofman PA, de Leeuw PW. Cerebral hyperperfusion syndrome[J]. Lancet Neurol, 2005, 4:877-888. [6] Zhao WG, Luo Q, Jia JB, Yu JL. Cerebral hyperperfusion syndrome after revascularization surgery in patients with moyamoya disease[J]. Br J Neurosurg, 2013, 27:321-325. [7] Fujimura M, Niizuma K, Endo H, Sato K, Inoue T, Shimizu H, Tominaga T. Quantitative analysis of early postoperative cerebral blood flow contributes to the prediction and diagnosis of cerebral hyperperfusion syndrome after revascularization surgery for moyamoya disease[J]. Neurol Res, 2015, 37:131-138. [8] Kazumata K, Uchino H, Tokairin K, Ito M, Shiga T, Osanai T, Kawabori M. Cerebral hyperperfusion syndrome after revascularization surgery in moyamoya disease:region-symptom mapping and estimating a critical threshold[J]. World Neurosurg, 2018, 114:e388-395. [9] Ishikawa T, Yamaguchi K, Kawashima A, Funatsu T, Eguchi S, Matsuoka G, Nomura S, Kawamata T. Predicting the occurrence of hemorrhagic cerebral hyperperfusion syndrome using regional cerebral blood flow after direct bypass surgery in patients with moyamoya disease[J]. World Neurosurg, 2018, 119:e750-756. [10] Kameyama M, Fujimura M, Tashiro R, Sato K, Endo H, Niizuma K, Mugikura S, Tominaga T. Significance of quantitative cerebral blood flow measurement in the acute stage after revascularization surgery for adult moyamoya disease:implication for the pathological threshold of local cerebral hyperperfusion[J]. Cerebrovasc Dis, 2020, 48:217-225. [11] Agarwal V, Singh P, Ahuja CK, Gupta SK, Aggarwal A, Narayanan R. Non-invasive assessment of cerebral microvascular changes for predicting postoperative cerebral hyperperfusion after surgical revascularisation for moyamoya disease:an arterial spin labelling MRI study[J]. Neuroradiology, 2021, 63:563-572. [12] Yang D, Zhang X, Tan C, Han Z, Su Y, Duan R, Shi G, Shao J, Cao P, He S, Wang R. Intraoperative transit-time ultrasonography combined with FLOW800 predicts the occurrence of cerebral hyperperfusion syndrome after direct revascularization of moyamoya disease:a preliminary study[J]. Acta Neurochir (Wien), 2021, 163:563-571. [13] Ge Sang DZ, Zhao JZ, Zhang D, Wang S, Zhao YL, Wang R. Studying change of regional cerebral blood flow after superficial temporal artery-middle cerebral artery anastomosis during acute stage in patients with moyamoya disease[J]. Zhonghua Yi Xue Za Zhi, 2012, 92:2046-2049.[格桑顿珠, 赵继宗, 张东, 王硕,赵元立, 王嵘. 烟雾病搭桥手术前后围手术期局部脑皮层血流动力学研究[J]. 中华医学杂志, 2012, 92:2046-2049.] [14] Li X, Qin ZZ, Niu JX, He X, Wang JZ. The analysis of postoperative complications and the influencing factors during the treatment of revascularization of moyamoya disease[J]. Yi Xue Yu Zhe Xue, 2016, 37:53-57.[李鑫, 秦至臻, 牛建星, 何心, 王建祯. 血管重建术治疗烟雾病术后并发症发生及其影响因素分析[J]. 医学与哲学, 2016, 37:53-57.] [15] Zhang G, Zhu SY, Ji ZY, Zhou PQ, Xu SC, Shi HZ. Research progress of cerebral hyperperfusion syndrome[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2017, 17:869-873.[张广, 朱仕逸, 季智勇, 周配权, 徐善才, 史怀璋. 脑过度灌注综合征研究进展[J]. 中国现代神经疾病杂志, 2017, 17:869-873.] [16] Zhao M, Deng X, Zhang D, Wang S, Zhang Y, Wang R, Zhao J. Risk factors for and outcomes of postoperative complications in adult patients with moyamoya disease[J]. J Neurosurg, 2018.[Epub ahead of print] [17] Hayashi K, Horie N, Suyama K, Nagata I. Incidence and clinical features of symptomatic cerebral hyperperfusion syndrome after vascular reconstruction[J]. World Neurosurg, 2012, 78:447-454. [18] Mukerji N, Cook DJ, Steinberg GK. Is local hypoperfusion the reason for transient neurological deficits after STA-MCA bypass for moyamoya disease[J]? J Neurosurg, 2015, 122:90-94. [19] Jung YJ, Ahn JS, Kwon DH, Kwun BD. Ischemic complications occurring in the contralateral hemisphere after surgical treatment of adults with moyamoya disease[J]. J Korean Neurosurg Soc, 2011, 50:492-496. |